Reduced annual bleed rates (ABRs) led to improvements in physical HRQoL among haemophilia patients with inhibitors.1,2 Patients on FEIBA prophylaxis showed a trend toward improvements in HRQoL versus those who received on-demand treatment, but this trend was not statistically significant.1,2*†
Learn about the PROOF Study design>>
The EQ-5D health profile showed the following trends† in percentage of prophylaxis patients reporting improved function when compared with the on-demand patients: mobility (17% vs. 6%), self-care (25% vs. 6%), and usual activities (25% vs. 12%), anxiety/depression (31% vs. 33%), and pain/comfort (19% vs. 17%).1,2†
ns=not significant
* The relatively small sample size limited the ability to detect significant differences in improvements between on-demand and prophylaxis groups.
† Not significant
‡ 12 months
§ When controlling for age and time.
In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more
Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more
FEIBA offers a long dosing interval. Read more
Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more
Learn how to dose FEIBA. Read more